Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib

Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib

Lorlatinib—a ROS1/ALK inhibitor—is currently undergoing clinical trials for the treatment of non-small cell lung cancers. Here the authors develop synthetic routes to11C- and 18F-labelled lorlatinib, with subsequent PET imaging showing good blood brain barrier permeability in non-human primates.

Bibliographic Details
Main Authors: Thomas Lee Collier, Marc D. Normandin, Nickeisha A. Stephenson, Eli Livni, Steven H. Liang, Dustin W. Wooten, Shadi A. Esfahani, Michael G. Stabin, Umar Mahmood, Jianqing Chen, Wei Wang, Kevin Maresca, Rikki N. Waterhouse, Georges El Fakhri, Paul Richardson, Neil Vasdev
Format: Article
Language:English
Published: Nature Publishing Group 2017-06-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/ncomms15761

Internet

https://doi.org/10.1038/ncomms15761

Similar Items